Business briefs: Amgen and Omnicom Group

Share this article:

Amgen released an outline of their long-term strategy last Thursday, with a focus on how they will continue to spread out their efforts on two different commercial models: biologics and biosimilars. "The company is clearly straddling two business opportunities that sometimes seem in conflict with each other -- a defender of the innovative products and a participant in biosimilar products. That tension is going to continue to be difficult for them to manage," said Sanford Bernstein analyst Geoffrey Porges. The Thousand Oaks-based drug manufacturer reported plans to launch six new biosimilars beginning in 2017.  Amgen also expects to deliver over $1 billion in new sales from new and emerging markets. The company plans to launch its first product in Chinese markets by 2015, and Japanese markets by 2016. In-market products, Prolia and XGEVA, saw a combined $1.2 billion in sales for 2012, which they expect to exceed $3 billion in revenue. Enbrel was cited as their leading and most valuable biologic.

Omnicom Group reported a decline of 1.3% in their Pharma and Healthcare business for 2012. The group as a whole saw an increase in revenue by 2.5% with domestic revenue increasing by 4.5% and international revenue increasing by .5%, year-over-year.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.